

S2 Table. Baseline characteristics of the validation cohort

	Total (n=88)	Low β 2M (< 4.1) (n=78)	High β 2M (\geq 4.1) (n=10)	p-value
Age (yr)				0.706
\leq 60	66 (75.0)	59 (75.6)	7 (70.0)	
$>$ 60	22 (25.0)	19 (24.3)	3 (30.0)	
Age (yr)	50 (17-78)	50 (17-78)	58.5 (21-75)	0.389
Sex				$>$ 0.999
Male	25 (28.4)	22 (28.2)	3 (30.0)	
Female	63 (71.5)	56 (71.7)	7 (70.0)	
ECOG PS				$<$ 0.001
0, 1	75 (85.2)	72 (92.3)	3 (30.0)	
\geq 2	13 (14.7)	6 (7.7)	7 (70.0)	
Ann Arbor stage				0.068
1, 2	60 (68.1)	56 (71.7)	4 (40.0)	
3, 4	28 (31.8)	22 (28.2)	6 (60.0)	
Lymph node involvement				0.365
None/regional	73 (82.9)	66 (84.6)	7 (70.0)	
Distant	15 (17.0)	12 (15.3)	3 (30.0)	
Non-nasal type				0.063
No	73 (82.9)	67 (85.8)	6 (60.0)	
Yes	15 (17.0)	11 (14.1)	4 (40.0)	
Bone marrow involvement				0.013
No	78 (88.6)	72 (92.3)	6 (60.0)	
Yes	10 (11.3)	6 (7.7)	4 (40.0)	
Serum LDH				$<$ 0.001
Normal	47 (53.4)	47 (60.2)	0	
Elevated	41 (46.5)	31 (39.7)	10 (100)	
Serum creatinine				0.033
Normal	85 (96.5)	77 (98.7)	8 (80.0)	
Elevated	3 (3.4)	1 (1.3)	2 (20.0)	
Epstein-Barr virus DNA in blood				0.087
Detectable	33 (37.5)	26 (33.3)	7 (70.0)	
Non-detectable	54 (61.3)	51 (65.3)	3 (30.0)	
Unknown	1 (1.1)	1 (1.3)	0	
Primary treatment				0.051
Chemotherapy	37 (42.0)	29 (37.1)	8 (80.0)	
CCRT followed by chemotherapy	44 (50.0)	42 (53.8)	2 (20.0)	
CCRT alone	7 (7.9)	7 (8.9)	0	
PINK risk group				0.015
PINK low	43 (48.8)	42 (53.8)	1 (10.0)	
PINK intermediate	23 (26.1)	18 (23.1)	5 (50.0)	
PINK high	22 (25.0)	18 (23.1)	4 (40.0)	
Extranodal involvement				0.223
0 or 1	59 (67.0)	54 (69.2)	5 (50.0)	
\geq 2	29 (32.9)	24 (30.7)	5 (50.0)	
Chemotherapy regimen ^{a)}				0.026
SMILE	23 (26.1)	17 (21.8)	6 (60.0)	

VIDL	37 (42.0)	36 (46.1)	1 (10.0)
VIPD	13 (14.7)	12 (15.3)	1 (10.0)
MIDDLE	8 (9.0)	6 (7.7)	2 (20.0)

Values are presented as number (%) or median (range). Chemotherapy regimen abbreviations: β 2M, β 2-microglobulin; CCRT, concurrent chemoradiotherapy; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; PINK, Prognostic Index for Natural Killer Lymphoma; PS, performance status.

^{a)}Excluding the patients who received concurrent chemoradiation monotherapy. SMILE, corticosteroid, methotrexate, ifosfamide, L-asparaginase, and etoposide; VIDL, etoposide, ifosfamide, dexamethasone, and L-asparaginase; VIPD, etoposide, ifosfamide, cisplatin, and dexamethasone; MIDDLE, methotrexate, ifosfamide, dexamethasone, L-asparaginase, and etoposide.